Thorac Cardiovasc Surg 2023; 71(S 01): S1-S72
DOI: 10.1055/s-0043-1761750
Monday, 13 February
Moderne Transplantationsmedizin

Treatment and Outcome of COVID-19 after Heart Transplantation: Update from a German Transplant Center

D. Oehler
1   Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
,
M. B. Immohr
2   Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
,
R. Bruno
1   Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
,
D. Sigetti
2   Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
,
J. Haschemi
1   Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
,
H. Aubin
2   Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
,
I. Tudorache
2   Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
,
R. Westenfeld
1   Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
,
F. Bönner
1   Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
,
M. Kelm
1   Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
,
A. Lichtenberg
2   Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
,
U. Boeken
2   Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
› Author Affiliations

Background: The SARS-CoV-2 pandemic is leading to hospitalizations and increased mortality worldwide. With potentially high prevalence and severity of COVID-19 in cardiac transplantation, there is a great need to generate data in this at-risk cohort. We report here our experience on outcome and treatment of heart transplant recipients infected with SARS-CoV-2 at a German transplant center longitudinally over the previous pandemic waves.

Method: All adult patients who had received a heart transplant at our center and had confirmed COVID-19 infection between December 2020 and July 2022 (n = 48) were included and retrospectively characterized.

Results: The median age was 60.5 (46.3–63.8) years, and the majority were male (83%). The hospitalization rate was 83%. Comorbidities included diabetes (31%), arterial hypertension (73%), and chronic renal failure (90%). The percentage of SARS-CoV-2 positive patients since the beginning of our vaccination campaign (03/2021) was 90%, while from those 43 patients, 88% were fully vaccinated at the time of infection (vaccine breakthrough). The median time from vaccination to infection within those patients was 138 (85–225) days. Antiviral therapy was given in 83% of all cases, and passive immunization (convalescent plasma/monoclonal antibodies) was performed in 98% of all cases. Oxygen administration was required in 10% of patients; only one patient required noninvasive ventilation (2%), and no patient required invasive ventilation or mechanical cardiovascular support (ECMO). No new cardiovascular or thromboembolic events were found, and we observed no COVID-19-associated mortality.

Conclusion: Under increasing numbers of vaccinated patients and treatment options, we could not detect severe courses or increased mortality of COVID-19 in heart transplanted patients. Prospective studies are needed to make better prognostic estimates of COVID-19 in (heart) transplanted patients in the future.



Publication History

Article published online:
28 January 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany